Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Nkarta Inc (NKTX)

Nkarta Inc (NKTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Nkarta to Participate in an Upcoming Investor Conference

NKTX : 2.44 (-2.40%)
Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights

NKTX : 2.44 (-2.40%)
Why Nkarta Stock Is Soaring Today

One analyst is now more bullish about this clinical-stage biotech stock.

RJF : 163.78 (+0.99%)
NKTX : 2.44 (-2.40%)
Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:AMGN),(NASDAQ:AMAM),(NASDAQ:ELEV),(NASDAQ:NKTX) EQNX::TICKER_END

ONCY : 0.9800 (-1.85%)
ONC.TO : 1.37 (-2.14%)
AMGN : 289.90 (+0.71%)
AMAM : 28.00 (+0.07%)
ELEV : 0.6052 (+4.15%)
NKTX : 2.44 (-2.40%)
Lupus Therapeutics Announces Partnership to Support the Evaluation of Natural Killer (NK) Cell Therapy in Lupus Nephritis

/PRNewswire/ -- Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, today announced a partnership with Nkarta, Inc. (Nasdaq:...

NKTX : 2.44 (-2.40%)
Why Shares of Nkarta Are Slumping Tuesday

The pharmaceutical stock dropped after announcing so-so clinical trial results.

CRSP : 46.29 (-2.05%)
NKTX : 2.44 (-2.40%)
Nkarta Announces Key Senior Leadership Team Appointments

Ralph Brandenberger, PhD, promoted to Chief Technical OfficerYvonne Li, MBA, promoted to Chief Administrative OfficerEvolution of Nkarta leadership team to...

NKTX : 2.44 (-2.40%)
Nkarta to Participate at Upcoming Investor Conference

SOUTH SAN FRANCISCO, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural...

NKTX : 2.44 (-2.40%)
Nkarta Appoints David R. Shook, MD, as Vice President, Clinical Development

SOUTH SAN FRANCISCO, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing...

NKTX : 2.44 (-2.40%)
Nkarta Reports First Quarter 2022 Financial Results and Corporate Highlights

Positive preliminary data reported from NKX101 Phase 1 study in patients with relapsed / refractory AML; 3 of 5 patients treated with a 3-dose regimen of...

NKTX : 2.44 (-2.40%)

Barchart Exclusives

Up 99% in the Past Year, How High Can This Growth Stock Rise?
With Lumentum shares skyrocketing over the past year, can this growth stock keep climbing? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar